Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Cambridge Cognition report 50% year-on year growth as interest in virtual clinical trials grows

Cambridge Cognition report 50% year-on year growth as interest in virtual clinical trials grows

Cambridge Cognition Holdings PLC (AIM:COG) (LON:COG) CEO Matthew Stork talks to Proactive London's Katie Pilbeam about their operations as well as their interim results for the six months ended 30 June 2021.

The company develops and markets digital solutions to assess brain health and enjoyed a strong and profitable first half, delivering revenues of £4.5 million, a 50% year-on year growth.

Order intake was above the Board’s expectations at £8.6 million and this included two substantial orders outside the Company’s core area of focus that totalled £3.6 million.

As stork explains the pandemic has accelerated interest in virtual clinical trials, with testing performed at home rather than in-clinic, and, as a result, orders for home testing solutions grew.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK